Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.82
+0.03001.08%
Post-market: 2.76-0.0600-2.13%16:10 EDT
Volume:243.08K
Turnover:689.36K
Market Cap:299.80M
PE:-7.20
High:2.88
Open:2.83
Low:2.80
Close:2.79
Loading ...

MaxCyte Inc - FY24 Net Loss $41.1 Mln VS Loss of $37.9 Mln in 2023

THOMSON REUTERS
·
12 Mar

MaxCyte Inc - Sees 2025 Core Revenue to Grow 8% to 15% Compared to 2024

THOMSON REUTERS
·
12 Mar

MaxCyte Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Mar

MaxCyte’s Strategic Expansion and Financial Resilience Drive Buy Rating

TIPRANKS
·
12 Mar

MaxCyte reports Q4 EPS (10c), consensus (12c)

TIPRANKS
·
12 Mar

MaxCyte sees FY25 core business revenue up 8%-15%

TIPRANKS
·
12 Mar

MaxCyte Q4 2024 GAAP EPS $(0.10) Beats $(0.12) Estimate, Sales $8.693M Beat $7.993M Estimate

Benzinga
·
12 Mar

MaxCyte Inc Qtrly Loss per Share $0.10

THOMSON REUTERS
·
12 Mar

MaxCyte Inc Q4 Shr View $-0.12 -- Lseg Ibes Data

THOMSON REUTERS
·
12 Mar

MaxCyte Inc Outlook Core Revenue Is Expected to Grow 8% to 15% in 2025 Compared to 2024

THOMSON REUTERS
·
12 Mar

BRIEF-MaxCyte Q4 Revenue USD 8.7 Million Vs. IBES Estimate USD 7.93 Million

Reuters
·
12 Mar

MaxCyte Q4 Gross Profit USD 6.4 Million

THOMSON REUTERS
·
12 Mar

MaxCyte Q4 Adjusted Ebitda USD -11.8 Million

THOMSON REUTERS
·
12 Mar

MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
08 Mar

MaxCyte Expands Stock Capital with New Issuance

TIPRANKS
·
04 Mar

MaxCyte Experiences Shift in Major Holdings by BlackRock

TIPRANKS
·
15 Feb

BlackRock Increases Stake in MaxCyte to 7.66%

TIPRANKS
·
14 Feb

BlackRock Adjusts Holdings in MaxCyte, Inc.

TIPRANKS
·
13 Feb

Craig-Hallum Sticks to Their Buy Rating for MaxCyte (MXCT)

TIPRANKS
·
13 Feb

MaxCyte enters strategic platform license with TG Therapeutics

TIPRANKS
·
12 Feb